Aims: Many individuals with cocaine use disorders also use alcohol and tobacco. A recent study conducted by NIDA’s Clinical Trials Network investigated pharmacotherapy for treatment of cocaine use disorders and also assessed alcohol and tobacco use. (Source: Drug and Alcohol Dependence)

Aims: Buprenorphine/naloxone (BUP/NX) was designed to prevent misuse by the intravenous (IV) route, as high naloxone IV bioavailability may precipitate withdrawal. We previously demonstrated that intranasal (IN) administration of BUP/NX results in appreciable absorption of naloxone. The present study explored whether IN BUP/NX has lower abuse potential and reinforcing efficacy compared to IN BUP alone in opioid dependent individuals. (Source: Drug and Alcohol Dependence)

Aims: The Cocaine Use Reduction with Buprenorphine (CURB) study, conducted under the National Drug Abuse Treatment Clinical Trials Network, investigated the safety and effectiveness of buprenorphine/naloxone (BUP, as Suboxone®) provided on a platform of extended-release injectable naltrexone (XR-NTX, as Vivitrol®) for reducing cocaine use in participants who met DSM- IV criteria for cocaine dependence and past or current opioid dependence or abuse. (Source: Drug and Alcohol Dependence)

Aims: To evaluate the tolerability, acceptability, and potential efficacy of the selective norepinephrine transporter inhibitor atomoxetine for treating amphetamine-type stimulant (ATS) use disorder in patients receiving buprenorphine/naloxone (BUP/NX). (Source: Drug and Alcohol Dependence)

Pain. It’s a nearly unavoidable part of the human experience. Whether it comes as the result of an injury or accident, surgery, or a health issue such as a headache or infection, arthritis, or fibromyalgia, pain can interfere with the ability to sleep, work, and enjoy life.
There are many ways to treat pain. Opioid drugs are one of them. Some examples include hydrocodone (used in Vicodin), oxycodone (used in Percocet), methadone, codeine, and morphine. These prescription drugs reduce the brain’s recognition of pain by binding to certain receptors in the body. In many situations, opioids are a reasonable choice for controlling pain — for example, severe pain caused by cancer.
Part of the problem is that a person can develop a tolerance to these drugs. Over time, higher and higher dose…

Pain. It’s a nearly unavoidable part of the human experience. Whether it comes as the result of an injury or accident, surgery, or a health issue such as a headache or infection, arthritis, or fibromyalgia, pain can interfere with the ability to sleep, work, and enjoy life.
There are many ways to treat pain. Opioid drugs are one of them. Some examples include hydrocodone (used in Vicodin), oxycodone (used in Percocet), methadone, codeine, and morphine. These prescription drugs reduce the brain’s recognition of pain by binding to certain receptors in the body. In many situations, opioids are a reasonable choice for controlling pain — for example, severe pain caused by cancer.
Part of the problem is that a person can develop a tolerance to these drugs. Over time, higher and higher dose…

We analyzed cost effectiveness of buprenorphine/naloxone combination and sustained release (SR) morphine when compared to methadone in patients treated for opioid dependence in Slovenia. To compare the expected costs of treatment with buprenorphine/naloxone combination and SR morphine, we also performed cost-minimization analysis. (Source: Value in Health)

We analyzed cost effectiveness of buprenorphine/naloxone combination and sustained release (SR) morphine when compared to methadone in patients treated for opioid dependence in Slovenia. To compare the expected costs of treatment with buprenorphine/naloxone combination and SR morphine, we also performed cost-minimization analysis. (Source: Value in Health)

Standard-of-care for opioid addiction is substitution therapy with methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets tighten, this study explored how emerging brands may gain a foothold in this increasingly generic market, as payers and prescribers balance clinical need with limited funds. (Source: Value in Health)

Standard-of-care for opioid addiction is substitution therapy with methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets tighten, this study explored how emerging brands may gain a foothold in this increasingly generic market, as payers and prescribers balance clinical need with limited funds. (Source: Value in Health)